Program
Moxifloxacin
Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.
Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.
Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 200 open or running | phase 4since Jun 26, 2007 | Nov 21, 2006 | none ahead |
| Alconits history only | 140 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Jul 10, 2007 | Jul 10, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Oct 8, 2009 | Oct 8, 2009 | none ahead |
| Da Volterraits history only | 20 open or running | phase 1since Jun 25, 2014 | Jun 25, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 21 open or running | phase 3since Jul 30, 2025 | Apr 9, 2024 | none ahead |
| Richmond Pharmacologyits history only | 20 open or running | phase 1since Jun 19, 2012 | Jun 19, 2012 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Jan 1, 2016 | Jan 1, 2016 | none ahead |
| Jason Ahee, M.D.its history only | 11 open or running | phase 3since Aug 4, 2017 | Aug 4, 2017 | Oct 2030phase 3 · NCT03244072 |
| Research Insightits history only | 10 open or running | phase 4since Dec 18, 2019 | Dec 18, 2019 | none ahead |
| Richmond Research Instituteits history only | 10 open or running | phase 1since Nov 8, 2013 | Nov 8, 2013 | none ahead |
Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 21, 2006.
- May 14, 2007Phase 3 study in Lung DiseasesNCT00473460 · 1,404 enrolled · United States, Andorra, Argentina and more
- Jun 26, 2007Phase 4 study in SinusitisNCT00493038 · 293 enrolled · Italy
- Jun 26, 20072 phase 3 studiesNCT00492726, NCT00492024
- Apr 4, 20083 phase 4 studiesNCT00656747, NCT00665327, NCT00668304
- May 21, 2008Phase 3 study in Pelvic Inflammatory DiseaseNCT00683865 · 749 enrolled · Denmark, Finland, France and more
- Jul 16, 2008Phase 3 study in PneumoniaNCT00717561 · 60 enrolled · Italy
- Oct 7, 2008Phase 3 study in Intraabdominal InfectionsNCT00769171 · 364 enrolled · China, Hong Kong, Indonesia and more
- Jan 23, 2009Phase 3 study in Communicable DiseasesNCT00828971 · 16 enrolled · Italy
- Nov 12, 2009Phase 1 study in QTc EvaluationNCT01014247 · 56 enrolled · Australia, Germany, Singapore and more
- Jan 8, 2010Phase 3 study in Pneumonia, AspirationNCT01045902 · 139 enrolled · Germany
- Jan 13, 2010Phase 1 study in InfectionsNCT01049022 · 31 enrolled · United States
- Feb 15, 2010Phase 3 study in Intraabdominal InfectionsNCT01069900 · 458 enrolled · United States, Argentina, Bulgaria and more
- Feb 22, 2010Phase 1 study in HealthyNCT01073891 · 24 enrolled · Germany
- Jul 28, 2022Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT05481528 · 51 enrolled · Germany
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 20 Bayer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Feb 7, 2023 | 51 |
| NCT01073891Healthy · Germany | 1 | Completed | Nov 2010 | 24 |
| NCT01069900Intraabdominal Infections · United States, Argentina, Bulgaria and more | 3 | Completed | Jan 21, 2015 | 458 |
| NCT01049022Infections · United States | 1 | Completed | Dec 2012 | 31 |
| NCT01045902Pneumonia, Aspiration · Germany | 3 | Completed | 139 | |
| NCT01014247QTc Evaluation · Australia, Germany, Singapore and more | 1 | Completed | Jun 2010 | 56 |
| NCT00828971Communicable Diseases · Italy | 3 | Completed | Sep 2009 | 16 |
| NCT00769171Intraabdominal Infections · China, Hong Kong, Indonesia and more | 3 | Completed | Dec 2006 | 364 |
| NCT00717561Pneumonia · Italy | 3 | Completed | May 2009 | 60 |
| NCT00683865Pelvic Inflammatory Disease · Denmark, Finland, France and more | 3 | Completed | Oct 2004 | 749 |
| NCT00668304Maxillary Sinusitis · United States, Argentina | 4 | Completed | 192 | |
| NCT00665327Pneumonia · United States, Puerto Rico | 4 | Completed | Apr 2004 | 401 |
| NCT00656747Bronchitis, Chronic · Andorra, Argentina, Australia and more | 4 | Completed | Dec 2010 | 1,372 |
| NCT00493038Sinusitis · Italy | 4 | Terminated | Jan 2008 | 293 |
| NCT00492726Infections · Argentina, Belgium, Bulgaria and more | 3 | Completed | Feb 2009 | 804 |
| NCT00492024Sinusitis · United States | 3 | Completed | Mar 2008 | 374 |
| NCT00473460Lung Diseases · United States, Andorra, Argentina and more | 3 | Completed | Jan 2007 | 1,404 |
| NCT00453349Pelvic Inflammatory Disease · China, Indonesia, Korea, Republic of and more | 3 | Completed | May 2008 | 460 |
| NCT00431678Pneumonia · Argentina, Belgium, Chile and more | 3 | Completed | Jul 2005 | 738 |
| NCT00402727Abscess · Austria, Belgium, Bulgaria and more | 3 | Completed | Jun 2008 | 813 |
How it is read
Names in the registry
- “Moxifloxacin”, 32 entries
- “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
- “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
- “moxifloxacin”, 6 entries
- “Moxidex otic solution”, 5 entries
Conditions, from the studies’ own filings
- Cataract, 6 studies
- Conjunctivitis, Bacterial, 5 studies
- Otitis Media, 4 studies
- Sinusitis, 3 studies
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.